CXCL2 and hepatocellular carcinoma: More importantly, our combination therapy of CXCL2 overexpression and anti‐PD‐1 reagent also demonstrated powerful therapeutic effects, with much more antitumor neutrophils and CD8+ T cells infiltration to retard HCC progression.